MULTI-ASSET

WHY CHOOSE US

Janus Henderson Multi-Asset includes teams in the UK and the US. In the UK, we have asset allocation specialists, traditional multi-manager investors and those focused on alternative asset classes, In the US, our teams manage US and global asset allocation strategies.

CAPABILITIES

Asset Allocation

The relationship between risk and reward is central to the Multi-Asset team’s thinking. They are responsible for managing portfolios comprised of different asset classes, usually via investment in third party funds and investment vehicles but in some cases through direct holdings. Over the years, they have honed their skills in following asset classes, using a combination of proprietary models that digest and interpret market, economic, and technical data. This is then overlaid with their own qualitative views on the markets and their assessment of funds and external managers.

LATEST FIXED INCOME INSIGHTS

Brexit parliament 3

UK election reaction: continuity and change

December 13, 2019

Paul O’Connor, Head of the UK Multi-Asset Team, gives his reaction to the UK election result and what it means for the Brexit process.

Read More
Ashwin Alankar, Ph.D. | Janus Henderson Investors

Tell Tail Signs: November 2019 – Don’t bet on recession or disinflation

December 2, 2019

​Janus Henderson’s US-based Multi-Asset Solutions Team present their latest Tail Risk Report, using options market prices to infer expected tail gains and losses for each asset class.

Read More

Draghi: whatever he could

October 22, 2019

Oliver Blackbourn, a portfolio manager on the UK-based Multi-Asset Team, comments on the imminent departure of Mario Draghi’s as ECB leader on 31 October 2019, as the ECB itself potentially reaches the limits of what it can achieve using the levers of monetary policy.

Read More

In-depth feature

Test tubes | Navigating the drug pricing debate | Janus henderson Investors

Navigating the drug pricing debate

August 3, 2018 | Comments Off on Navigating the drug pricing debate

When the Trump administration introduced a ‘blueprint’ to lower drug prices in May, the pharmaceutical industry breathed a sigh of relief. Andy Acker and Ethan Lovell, Portfolio Managers of the Global Life Sciences strategy, discuss.

Read More